Walleye Capital
AXSM icon

Walleye Capital’s Axsome Therapeutics AXSM Stock Holding History

Walleye Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
+4,700
New +$1.02M ﹤0.01% 1995
2026
Q1 		– Sell
-1,400
Closed -$256K – 4384
2025
Q4 		$256K Buy
1,400
+500
+56% +$69.8K ﹤0.01% 3408
2025
Q3 		$109K Sell
900
-4,800
-84% -$541K ﹤0.01% 3668
2025
Q2 		$595K Buy
5,700
+3,500
+159% +$371K ﹤0.01% 2491
2025
Q1 		$257K Buy
2,200
+1,700
+340% +$194K ﹤0.01% 3075
2024
Q4 		$42.3K Sell
500
-700
-58% -$64.4K ﹤0.01% 4392
2024
Q3 		$108K Sell
1,200
-500
-29% -$43.6K ﹤0.01% 4370
2024
Q2 		$137K Sell
1,700
-6,100
-78% -$452K ﹤0.01% 4547
2024
Q1 		$622K Buy
7,800
+6,600
+550% +$554K ﹤0.01% 3008
2023
Q4 		$95.5K Sell
1,200
-4,000
-77% -$267K ﹤0.01% 4059
2023
Q3 		$363K Buy
5,200
+400
+8% +$29.9K ﹤0.01% 3071
2023
Q2 		$345K Buy
+4,800
New +$354K ﹤0.01% 2695
2023
Q1 		– Sell
-11,600
Closed -$895K – 3932
2022
Q4 		$895K Buy
11,600
+8,100
+231% +$484K 0.02% 1066
2022
Q3 		$156K Buy
+3,500
New +$175K ﹤0.01% 2240

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's AXSM Position: Q2 2026 in Review

Walleye Capital reduced its Axsome Therapeutics (AXSM) stake by 95% in Q2 2026, selling an estimated $7.24M and leaving 1,716 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

Walleye Capital first reported a position in AXSM in Q3 2018 and has held it in 14 quarters since. The position peaked at $17.6M in Q4 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Walleye Capital held 1,716 shares of Axsome Therapeutics worth $420K as of Q2 2026.
  • Walleye Capital sold 33,403 Axsome Therapeutics shares in Q2 2026, an estimated $7.24M.
  • Axsome Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2899 holding.
  • Walleye Capital first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 14 quarters since.
  • Walleye Capital's Axsome Therapeutics position peaked at $17.6M in Q4 2019.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.